trial

Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder

NCTId NCT03043820
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 110 (actual)
Sponsored by Iris Sommer
Primary completion 2021-07-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
110 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2016-08
Primary completion
2021-07-01
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Raloxifene

Sponsors

Iris SommerLead Sponsor
Julius CenterCollaborator
Rudolf Magnus Institute - University of UtrechtCollaborator
GGZ EindhovenCollaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Collaborator
GGZ CentraalCollaborator
Altrecht GGZCollaborator
Reinier van Arkel GroupCollaborator
Ziekenhuis Netwerk Antwerpen (ZNA)Collaborator

Investigators

3
Iris E.C. Sommer, Prof. Dr.Principal Investigator
Bob Oranje, Ass. Prof.Principal Investigator
Janna de Boer, MDStudy Chair

Sites

1 total
Utrecht, Netherlands

Linked catalysts

1
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder — primary completion2021-07-01

Facts & assertions

4 sourced
Enrollment
110
Phase
PHASE3
Primary Completion Date
2021-07-01
Status
COMPLETED
relationships
The graph out of here
drug
Raloxifene
drug
lead_sponsor
Iris Sommer
company
collaborator
Julius Center
company
Rudolf Magnus Institute - University of Utrecht
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Iris E.C. Sommer, Prof. Dr.
person
Bob Oranje, Ass. Prof.
person
Janna de Boer, MD
person